MedTrace Logo

Umbilical Cord Mesenchymal Stem Cell Improve Cardiac Function on ST-elevation Myocardial Infarction (STEMI) Patients

NCT05935423 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-07-07

No results posted yet for this study

Summary

The goal of this clinical trial is to learn about the effectiveness of Umbilical Cord Mesenchymal Stem Cell (UC MSC) therapy in patients with STEMI against infarct myocardial size reduction and prevent the incidence of heart failure in the future

Conditions

  • ST Elevation Myocardial Infarction

Interventions

BIOLOGICAL

Umbilical Cord Mesenchymal Stem Cell transplantation

50 million UC MSC will be transplanted 10-15 days after primary PCI

Sponsors & Collaborators

  • PT. Prodia Stem Cell Indonesia

    collaborator INDUSTRY

  • Indonesia University

    lead OTHER

Principal Investigators

  • Dede Moeswir · Fakultas Kedokteran Universitas Indonesia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-31
Primary Completion
2024-07-31
Completion
2024-07-31

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05935423 on ClinicalTrials.gov